Apexigen, Inc. Profile Avatar - Palmy Investing

Apexigen, Inc.

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development f…

Biotechnology
US, San Carlos [HQ]
Financials

Analysts

Reported
Past Estimate Consensus
Future Estimate Consensus
Apexigen, Inc. can't present any analysts estimates at the moment detail analysis.
End of APGN's Analysis
CIK: 1814140 CUSIP: - LEI: - UEI: -
Secondary Listings
APGN has no secondary listings inside our databases.